ACS：全球mRNA疫苗和治疗药物研究分析报告（英文版）（27页）.pdf

1、Messenger RNA-Based Therapeutics and Vaccines:Whats beyondCOVID-19?Dongqiao Li,Cynthia Liu,Yingzhu Li,Rumiana Tenchov,Janet M.Sasso,Di Zhang,Dan Li,Lixue Zou,Xuezhao Wang,*and Qiongqiong Zhou*Cite This:ACS Pharmacol.Transl.Sci.2023,6,943969Read OnlineACCESSMetrics&MoreArticle Recommendations*sSuppor

2、ting InformationABSTRACT:With the rapid success in the development ofmRNA vaccines against COVID-19 and with a number of mRNA-based drugs ahead in the pipelines,mRNA has catapulted to theforefront of drug research,demonstrating its substantial effective-ness against a broad range of diseases.As the

3、recent globalpandemic gradually fades,we cannot stop thinking about what theworld has gained:the realization and validation of the power ofmRNA in modern medicine.A significant amount of research hasnow been concentrated on developing mRNA drugs and vaccineplatforms against infectious and immune dis

4、eases,cancer,andother debilitating diseases and has demonstrated encouragingresults.Here,based on the CAS Content Collection,we provide alandscape view of the current state,outline trends in the researchand development of mRNA therapeutics and vaccines,and highlight some notable patents focusing on

5、mRNA therapeutics,vaccines,and delivery systems.Analysis of diseases disclosed in patents also reveals highly investigated diseases for treatments with thesemedicines.Finally,we provide information about mRNA therapeutics and vaccines in clinical trials.We hope this Review will beuseful for understa

6、nding the current knowledge in the field of mRNA medicines and will assist in efforts to solve its remainingchallenges and revolutionize the treatment of human diseases.KEYWORDS:mRNA,vaccine,therapeutic,COVID-19,infectious disease,cancerThe COVID-19 mRNA vaccines were developed andapproved at unprec